UK MHRA and Botanical Supplements: Where EBC-46 Fits in the UK Regulatory Framework

The United Kingdom has one of the most carefully structured regulatory environments for botanical products in the world. Buyers of dietary supplements containing blushwood berry extract — the natural source of EBC-46 — frequently ask where these products sit within UK law, and the answer depends on how a given product is marketed and what claims are attached to it. This article walks through the main UK frameworks relevant to botanical supplements and locates EBC-46 oral extracts within them.

The MHRA and the medicines borderline

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products in the UK. Under the Human Medicines Regulations 2012, a product is classified as a medicine if it is presented as having properties for treating or preventing disease, or if it is intended to restore, correct or modify physiological functions by pharmacological means. The MHRA publishes detailed borderline guidance to help manufacturers determine whether their product needs a marketing authorisation.

A blushwood berry extract sold as a dietary supplement — without therapeutic claims — generally sits outside the medicines framework. The moment a product is marketed with claims to treat, cure, or prevent specific diseases, the MHRA can reclassify it. Reputable supplement brands therefore stay scrupulously within dietary supplement labelling conventions, describing ingredients and traditional use rather than making therapeutic promises.

The Food Standards Agency and food supplement rules

Food supplements in Great Britain fall under the Food Safety Act 1990 and retained EU food law, enforced by the Food Standards Agency. The relevant regulations require supplements to be safe for consumption, accurately labelled with ingredients and recommended daily intake, and free from misleading claims. Health claims on supplements are only permitted if they appear on the GB Nutrition and Health Claims Register.

EBC-46 is not currently on the authorised health claims register, which means UK supplement suppliers cannot make specific health claims linking blushwood berry extract to any disease outcome. This is not a regulatory gap — it is the standard position for most botanical compounds, and it reflects the ordinary operation of food supplement law.

Traditional herbal medicine registration

The UK does offer a separate pathway for plant-based products that want to make limited traditional-use claims: the Traditional Herbal Medicines Registration Scheme (THMRS). To register, an ingredient must have documented traditional medicinal use in Europe for at least 30 years. Fontainea picrosperma does not have that documented European traditional use, so THMRS is not the relevant pathway for blushwood berry extract supplements at this time. The appropriate framework remains the food supplement regime.

What this means for buyers

UK consumers purchasing EBC-46 supplements should look for products that clearly label themselves as dietary supplements, carry a standard "not intended to diagnose, treat, cure or prevent any disease" style statement where applicable, and come with third-party lab verification of purity and safety. Brands such as Blushwood Health operate with Eurofins-verified batch testing, GMP-certified manufacturing, and physician-reviewed product information — all standards that align with the expectations of UK food supplement law, even though products are sold internationally.

The MHRA does not pre-approve individual supplement products, but enforcement action is most commonly triggered by aggressive disease claims rather than by the presence of novel botanicals themselves. Buyers who want to stay within sensible boundaries should favour suppliers that avoid therapeutic claims altogether and provide documentary evidence of product composition.

Bottom line

EBC-46 oral supplements sit within the UK food supplement framework, regulated primarily through the Food Standards Agency and local authority enforcement. The MHRA does not license these products as medicines, and brands that market them responsibly — with no therapeutic claims and published lab data — operate well within existing rules. For buyers, the practical signal is the same as it is globally: look for transparent labelling, independent testing, and a manufacturer that takes regulatory restraint seriously.

Sources

1. MHRA — A Guide to What is a Medicinal Product, UK Government, 2024.

2. Food Standards Agency — Food Supplements, FSA, 2025.

3. MHRA — Traditional Herbal Medicines Registration Scheme, UK Government, 2024.

Related Articles

EBC-46 2026 Global Regulatory Landscape Snapshot — comparative overview of regulatory positions across major jurisdictions.

EBC-46 Under DSHEA: The US Supplement Framework — how US law treats the same category of product.

Health Canada and EBC-46 Natural Health Product Rules — the equivalent framework in Canada.